173 related articles for article (PubMed ID: 21742898)
1. Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.
Li CM; Chen J; Lu Y; Narayanan R; Parke DN; Li W; Ahn S; Miller DD; Dalton JT
Drug Metab Dispos; 2011 Oct; 39(10):1833-9. PubMed ID: 21742898
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
Chen J; Wang Z; Li CM; Lu Y; Vaddady PK; Meibohm B; Dalton JT; Miller DD; Li W
J Med Chem; 2010 Oct; 53(20):7414-27. PubMed ID: 20919720
[TBL] [Abstract][Full Text] [Related]
3. Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles.
Li CM; Lu Y; Narayanan R; Miller DD; Dalton JT
Drug Metab Dispos; 2010 Nov; 38(11):2032-9. PubMed ID: 20675405
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.
Chen J; Li CM; Wang J; Ahn S; Wang Z; Lu Y; Dalton JT; Miller DD; Li W
Bioorg Med Chem; 2011 Aug; 19(16):4782-95. PubMed ID: 21775150
[TBL] [Abstract][Full Text] [Related]
5. Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor.
Li CM; Wang Z; Lu Y; Ahn S; Narayanan R; Kearbey JD; Parke DN; Li W; Miller DD; Dalton JT
Cancer Res; 2011 Jan; 71(1):216-24. PubMed ID: 21084278
[TBL] [Abstract][Full Text] [Related]
6. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents.
Lu Y; Li CM; Wang Z; Chen J; Mohler ML; Li W; Dalton JT; Miller DD
J Med Chem; 2011 Jul; 54(13):4678-93. PubMed ID: 21557538
[TBL] [Abstract][Full Text] [Related]
8. Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin.
Li CM; Lu Y; Ahn S; Narayanan R; Miller DD; Dalton JT
J Mass Spectrom; 2010 Oct; 45(10):1160-6. PubMed ID: 20814887
[TBL] [Abstract][Full Text] [Related]
9. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; White SW; Miller DD; Li W; Li W
J Med Chem; 2019 Jul; 62(14):6734-6750. PubMed ID: 31251599
[TBL] [Abstract][Full Text] [Related]
10. Simple monocyclic pyrimidine analogs as microtubule targeting agents binding to the colchicine site.
Choudhary S; Kaku K; Robles AJ; Hamel E; Mooberry SL; Gangjee A
Bioorg Med Chem; 2023 Mar; 82():117217. PubMed ID: 36889150
[TBL] [Abstract][Full Text] [Related]
11. Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis.
Wang Z; Chen J; Wang J; Ahn S; Li CM; Lu Y; Loveless VS; Dalton JT; Miller DD; Li W
Pharm Res; 2012 Nov; 29(11):3040-52. PubMed ID: 22410804
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
13. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.
Chen J; Ahn S; Wang J; Lu Y; Dalton JT; Miller DD; Li W
J Med Chem; 2012 Aug; 55(16):7285-9. PubMed ID: 22783954
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
Sun K; Sun Z; Zhao F; Shan G; Meng Q
Future Med Chem; 2021 May; 13(9):839-858. PubMed ID: 33821673
[TBL] [Abstract][Full Text] [Related]
16. Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site.
Dong M; Liu F; Zhou H; Zhai S; Yan B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27754459
[TBL] [Abstract][Full Text] [Related]
17. Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.
Wu JD; Cui YJ; Zhou YG; Tang LQ; Zhang CM; Liu ZP
Invest New Drugs; 2020 Feb; 38(1):29-38. PubMed ID: 30887253
[TBL] [Abstract][Full Text] [Related]
18. Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
Chen H; Deng S; Wang Y; Albadari N; Kumar G; Ma D; Li W; White SW; Miller DD; Li W
J Med Chem; 2020 Jan; 63(2):827-846. PubMed ID: 31860298
[TBL] [Abstract][Full Text] [Related]
19. 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents.
Chang JY; Hsieh HP; Chang CY; Hsu KS; Chiang YF; Chen CM; Kuo CC; Liou JP
J Med Chem; 2006 Nov; 49(23):6656-9. PubMed ID: 17154496
[TBL] [Abstract][Full Text] [Related]
20. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
